‘How did they get there first?’ Biotechs forced to learn new patent tricks to protect pipelines

For a biotech, your intellectual property is your most prized asset. But a new era of increased global competition means that strong patents, longer stealth periods and even some misdirection can be required to ensure drug developers retain an edge.

Source: FierceBiotech